POMDOCTOR LIMITED Announces First Half of Fiscal 2025 Unaudited Financial Results

Notably, our successful initial public offering (IPO) in October provided us with additional capital resources and expanded opportunities for future growth, further enriching our strategic options and strengthening our execution capabilities. Looking ahead, we are confident in our ability to continue improving operational performance and creating long-term value for our shareholders."

First Half of Fiscal 2025 Financial Summary

• Net revenues for the six months ended June 30, 2025 were RMB174.5 million (US$24.4 million), representing a 16.2% increase from RMB150.2 million in the six months ended June 30, 2024.
• Gross profit increased by 16.3% from RMB24.3 million in the six months ended June 30, 2024, to RMB28.3 million (US$4.0 million) in the six months ended June 30, 2025.
• Gross profit margin remained stable at 16.2% in the six months ended June 30, 2024 and 2025.
• Net loss was RMB19.9 million (US$2.8 million) for the six months ended June 30, 2025, compared with RMB14.0 million for the six months ended June 30, 2024.
• Net loss per share, basic and diluted, was RMB11.45 (US$1.60) for the six months ended June 30, 2025, compared with RMB10.58 for the six months ended June 30, 2024.

Unaudited Financial Results for the First Half of Fiscal 2025

• Net revenues for the six months ended June 30, 2025 were RMB174.5 million (US$24.4 million), representing a 16.2% increase from RMB150.2 million in the six months ended June 30, 2024, which was primarily attributable to the increase in the net revenues from Internet hospital. Net revenues from Internet hospital increased by 82.4% from RMB36.8 million in the six months ended June 30, 2024 to RMB67.2 million (US$9.4 million) in the six months ended June 30, 2025, primarily attributable to the increase in revenues generated from online pharmacy sales. In the first half of 2025, the Company strengthened its cooperation with pharmaceutical manufacturers to sell their products through its Internet hospital platform. As a result, revenue from the Company's online pharmacy sales increased from RMB36.3 million in the six months ended June 30, 2024 to RMB66.4 million (US$9.3 million) in the six months ended June 30, 2025.
• Cost of revenues increased by 16.2% from RMB125.8 million in the six months ended June 30, 2024 to RMB146.2 million (US$20.4 million) in the six months ended June 30, 2025, primarily due to the increase in cost of revenues in online pharmacy sales from RMB20.4 million in the six months ended June 30, 2024 to RMB40.0 million (US$5.6 million) in the six months ended June 30, 2025, which was in line with the increase in the Company's net revenues from Internet hospital.
• Gross profit increased by 16.3% from RMB24.3 million for the six months ended June 30, 2024, to RMB28.3 million (US$4.0 million) in the six months ended June 30, 2025.
• Gross profit margin remained stable at 16.2% in the six months ended June 30, 2024 and 2025. The gross profit margin of the Company's Internet hospital decreased from 44.7% in the six months ended June 30, 2024 to 40.5% in the six months ended June 30, 2025, mainly due to the increase in the online pharmacy sales of products with lower gross profit margin. The gross profit margin of the Company's pharmaceutical supply chain business decreased from 6.9% in the six months ended June 30, 2024 to 1.1% in the six months ended June 30, 2025, which was primarily because the gross profit margin of the Company's pharmacy wholesale customers newly acquired in the six months ended June 30, 2024 was higher than that of customers in the six months ended June 30, 2025.
• Sales and marketing expenses increased by 11.6% from RMB24.9 million in the six months ended June 30, 2024 to RMB27.8 million (US$3.9 million) in the six months ended June 30, 2025, primarily due to higher service fees to doctors and increased staff costs in line with the growth in revenues from Internet hospital business, partially offset by a slight decrease in advertising and promotion costs resulting from a relatively stable pharmaceutical supply chain business.
• General and administrative expenses increased by 53.5% from RMB6.8 million in the six months ended June 30, 2024 to RMB10.5 million (US$1.5 million) in the six months ended June 30, 2025, primarily due to the increase in consultancy and professional service fees incurred in connection with the Company's initial public offering, partially offset by the decrease in expected credit loss recognized resulting from the efforts for collection of receivables.
• Research and development expense remained relatively stable at RMB1.5 million (US$0.2 million) for the six months ended June 30, 2024 and 2025.
• Impairment loss on long-lived assets recorded was RMB0.02 million and RMB2.0 million (US$0.3 million) for the six months ended June 30, 2024 and 2025, respectively.
• Loss from operation was RMB13.5 million (US$1.9 million) for the six months ended June 30, 2025, compared with RMB8.9 million for the six months ended June 30, 2024.
• Net loss was RMB19.9 million (US$2.8 million) for the six months ended June 30, 2025, compared with RMB RMB14.0 million for the six months ended June 30, 2024.
• Net loss per share, basic and diluted, was RMB11.45 (US$1.60) for the six months ended June 30, 2025, compared with RMB10.58 for the six months ended June 30, 2024.

Financial Condition

• Cash and cash equivalents of RMB5.7 million (US$0.8 million) as of June 30, 2025, compared to RMB7.7 million as of December 31, 2024.
• Net cash used in operating activities was RMB15.0 million (US$2.1 million) for the six months ended June 30, 2025, compared with RMB10.6 million for the six months ended June 30, 2024.
• Net cash used in investing activities was RMB512,200 (US$71,500) for the six months ended June 30, 2025, compared with RMB17,862 for the six months ended June 30, 2024.
• Net cash provided by financing activities was RMB13.6 million (US$1.9 million) for the six months ended June 30, 2025, compared with RMB16.6 million for the six months ended June 30, 2024.

Exchange Rate Information

This announcement contains translations of certain RMB amounts into U.S. dollars at a specified rate solely for the convenience of the reader. Unless otherwise noted, all translations from RMB to U.S. dollars are made at a rate of RMB7.1636 to US$1.00, the rate set forth in the H.10 statistical release of the U.S. Federal Reserve Board on June 30, 2025.

Recent Development

On October 9, 2025, the Company completed its initial public offering (the "Offering") of 5,000,004 American Depositary Shares ("ADSs") at a public offering price of US$4.00 per ADS. On October 10, 2025, the underwriter of the Offering fully exercised its over-allotment option to purchase an additional 750,000 American Depositary Shares of the Company at the public offering price of US$4.00 per share. The gross proceeds were US$23,000,016 from the Offering, before deducting underwriting discounts and commissions, and other expenses. The Company's ADSs began trading on the Nasdaq Global Market on October 8, 2025 under the ticker symbol "POM."

About POMDOCTOR LIMITED

POMDOCTOR LIMITED is a leading online medical services platform for chronic diseases in China, ranking sixth on China's Internet hospital market based on the number of contracted doctors in 2022, according to Frost & Sullivan. Focusing on chronic disease management and pharmaceutical services, the Company offers a one-stop platform for medical services, organically connecting patients with doctors and pharmaceutical products. The Company's operations primarily include Internet hospital and pharmaceutical supply chain, connecting users, pharmacies, suppliers, medical professionals, and other healthcare participants. Through this model, POMDOCTOR aims to enhance the efficiency and transparency of the healthcare value chain. The Company's mission is to provide effective prevention and treatment solutions to alleviate patients' sufferings from illnesses. Its vision is to become the most trustworthy medical and healthcare services platform. For more information, please visit the Company's website: http://ir.7shiliu.com.

Forward-Looking Statements

Certain statements in this announcement are forward-looking statements. These forward-looking statements involve known and unknown risks and uncertainties and are based on the Company's current expectations and projections about future events that the Company believes may affect its financial condition, results of operations, business strategy and financial needs. Investors can find many (but not all) of these statements by the use of words such as "approximates," "believes," "hopes," "expects," "anticipates," "estimates," "projects," "intends," "plans," "will," "would," "should," "could," "may" or other similar expressions. The Company undertakes no obligation to update or revise publicly any forward-looking statements to reflect subsequent occurring events or circumstances, or changes in its expectations, except as may be required by law. Although the Company believes that the expectations expressed in these forward-looking statements are reasonable, it cannot assure you that such expectations will turn out to be correct, and the Company cautions investors that actual results may differ materially from the anticipated results and encourages investors to review other factors that may affect its future results in the Company's filings with the SEC.

For more information, please contact:

POMDOCTOR LIMITED
Investor Relations Department
Email: ir@7lk.com

Ascent Investor Relations LLC
Tina Xiao
Phone: +1-646-932-7242
Email: investors@ascent-ir.com

View original content:https://www.prnewswire.com/news-releases/pomdoctor-limited-announces-first-half-of-fiscal-2025-unaudited-financial-results-302632067.html

SOURCE POMDOCTOR LIMITED